Multiple Tumor Types

Viewing Page 3 of 7 | Showing Results 21 - 30 of 61

Procurement and Research Evaluation of Human Blood and Tissues for Detection of Occult Malignancies Using the Polymerase Chain Reaction (PCR) and Proteomics

Patient specimens (archived paraffin-embedded and frozen specimens and blood/body fluid samples) will be accrued from patients at John Wayne Cancer...

Dave Hoon, Ph.D
  • John Wayne Cancer Institute (JWCI)
  • Providence St. Johns Health Center (PSJHC)

A PHASE 1/2A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND ANTITUMOR ACTIVITY OF GEN-009 ADJUVANTED VACCINE IN ADULT PATIENTS WITH SELECTED SOLID TUMORS

This study is designed to assess the performance of rhPSMA-7.3 (18F) for detecting N1 andM1 disease in patients with newly diagnosed PCa eligible...

Przemyslaw Twardowski
  • John Wayne Cancer Institute (JWCI)
  • Providence St. Johns Health Center (PSJHC)

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and...

Gary Goodman, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Montana, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors with Specific Genomic Aberrations

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant.Inclusion Criteria:• High risk smoldering myeloma, which is...

Thomas Brown, M.D.
  • Swedish Medical Center

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult...

Brendan Curti, M.D.
  • Providence Cancer Institute Franz Clinic

QUILT-3.055: A Phase IIb, Single-Arm, Multicohort, Open-Label Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients Who Have Disease Progression Following an Initial Response to Treatment With PD-1/PD-L1 Checkpoint Inhibitor Therapy

This is a Phase IIb, single-arm, multicohort, open-label multicenter study of ALT-803 in combination with an FDA-approved PD-1/PD-L1 checkpoint...

Rom Leidner, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced/Metastatic Solid Tumors who are refractory to Available Standard...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies....

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Montana, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX -2011 and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer

JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic
Viewing Page 3 of 7 | Showing Results 21 - 30 of 61